Form 4: 908 Devices Director E. Kevin Hrusovsky Reports Significant Equity Transactions

E. Kevin Hrusovsky, a Director at 908 Devices Inc., reported the vesting and conversion of 11,364 Restricted Stock Units into common stock, alongside the grant of 14,083 new RSUs and 6,516 stock options.

Summary

• Director E. Kevin Hrusovsky reported multiple equity transactions with 908 Devices Inc. (MASS).
• On June 11, 2025, 11,364 Restricted Stock Units (RSUs) vested and were converted into common stock.
• Following this conversion, Hrusovsky's direct beneficial ownership of common stock increased to 151,307 shares.
• Additionally, 329,675 shares are indirectly owned through the E. Kevin Hrusovsky 2012 Irrevocable Trust.
• On June 12, 2025, Hrusovsky was granted 14,083 new RSUs.
• Also on June 12, 2025, Hrusovsky was granted 6,516 stock options with an exercise price of $7.19.

Sentiment

Score: 7

Explanation: The filing indicates ongoing equity compensation for a director, aligning management interests with shareholders, which is generally positive. It's a routine disclosure without negative surprises.

Positives

• Director E. Kevin Hrusovsky received new equity grants (14,083 RSUs and 6,516 stock options), indicating continued alignment of interests with shareholders.
• The vesting of 11,364 RSUs demonstrates the realization of previously granted compensation.

Future Outlook

The newly granted 14,083 Restricted Stock Units are scheduled to vest fully on June 12, 2026, or the day prior to the 2026 Annual Meeting of Stockholders, contingent on continued service. The 6,516 stock options will vest in substantially equal monthly installments over 12 months following June 12, 2025, also subject to continued service, and expire on June 11, 2035.

Management Comments

• The filing was signed by Michael S. Turner, as Attorney-in-Fact for E. Kevin Hrusovsky.

Industry Context

This Form 4 filing details routine insider equity compensation and ownership changes for a director at 908 Devices Inc., a common occurrence in publicly traded companies as part of executive compensation and retention strategies.

Comparison to Industry Standards

• Form 4 filings are standard regulatory disclosures for insider transactions across all publicly traded companies in the U.S.
• The specific terms of equity grants (e.g., RSU vesting schedules, option exercise prices) are typically benchmarked against peer companies within the life sciences or analytical instrumentation sector, such as Thermo Fisher Scientific, Agilent Technologies, or Waters Corporation, to ensure competitive executive compensation. However, this document does not provide sufficient detail to perform such a comparative analysis.

Related Party Transactions

• The indirect ownership of 329,675 shares through the E. Kevin Hrusovsky 2012 Irrevocable Trust, where the reporting person's spouse and children are trustees, constitutes a related party arrangement for beneficial ownership purposes.

Stakeholder Impact

• Shareholders: The grant of new equity to a director aligns management incentives with shareholder interests, potentially encouraging long-term value creation.

Next Steps

• Continued service by E. Kevin Hrusovsky for vesting of new RSUs and stock options.
• Future vesting of 14,083 RSUs on June 12, 2026, or prior to the 2026 Annual Meeting.
• Monthly vesting of 6,516 stock options over 12 months starting June 12, 2025.

Key Dates

Recommendation

Keywords

908 Devices Inc., MASS, SEC Form 4, Insider Trading, Restricted Stock Units, RSU, Stock Options, Equity Compensation, Director, Beneficial Ownership, E. Kevin Hrusovsky